financetom
Business
financetom
/
Business
/
HALO Dream Inc. Acquires Child Craft, Expanding Its Premium Nursery Portfolio
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
HALO Dream Inc. Acquires Child Craft, Expanding Its Premium Nursery Portfolio
Sep 16, 2025 4:11 AM

LOS ANGELES and NEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) -- HALO Dream Inc. (“HALO”), a portfolio company of Transom Capital Group (“Transom”), is proud to announce the acquisition of Child Craft, a beloved and iconic brand known for its high-quality wood nursery furniture and decor. Child Craft’s products include cribs, beds, dressers and other essentials that have earned the trust of American families for generations.

This acquisition marks HALO’s third in just 16 months, following the successful integrations of BreathableBaby (May 2024) and Baby Merlin (March 2025). Together, these acquisitions reinforce HALO’s commitment to delivering premium juvenile sleep solutions that help babies—and their parents—sleep better and longer. The acquired product line will be transitioned to the HALO brand.

“Since 1954, Child Craft has been synonymous with safety, comfort, and style,” said Walter Lehneis, CEO of HALO. “We’re thrilled to welcome this trusted brand to the HALO family. Child Craft aligns perfectly with our mission, and we look forward to investing to grow our presence in the nursery decor category.”

“Transom is committed to supporting HALO’s growth and market leadership, and we’re excited to help HALO scale its premium nursery offerings through this acquisition,” said Rob Papetti, Senior Vice President at Transom. “Child Craft expands HALO’s sleep-focused product portfolio with the addition of high-quality, well-appointed wood designs, aligning perfectly with HALO’s mission of delivering safe, trusted products that both parents and babies love.”

Legal counsel was provided by Honigman LLP. Financing for the acquisition was supported by Wingspire Capital LLC and Blue Torch Capital LP.

About Transom

Transom is a leading operationally focused private equity firm that thrives in complexity, specializing in identifying and unlocking value in the middle market. Founded in 2008 and headquartered in Los Angeles, Transom has established a strong track record across various economic cycles by employing a time-tested, operationally intensive strategy to drive transformative outcomes. Transom’s expertise spans corporate carve-outs, lender-owned businesses, and other complex situations requiring speed, flexibility, and precision. Supported by a large in-house operations team, Transom delivers tailored solutions backed with functional expertise to help companies unlock their full potential.

Transom’s sector-flexible approach is grounded in pattern recognition, value creation, and disciplined execution. The firm provides not only capital, but also the tools, insights, and operational capabilities necessary to accelerate performance and create long-term value.

For more information, visit www.transomcap.com.

About HALO

Headquartered in New York City, HALO Dream Inc. is a designer, developer, marketer and distributor of juvenile sleep products, including swaddles, wearable blankets, bassinets, cribs, crib liners and mattresses. These industry-leading products offer innovations that make safer, longer and healthier sleep easier for both parents and babies. For more information, visit https://halosleep.com.

Media Contacts

Daley PR for HALO

[email protected]

FGS Global for Transom

[email protected]

Image: https://www.globenewswire.com/newsroom/ti?nf=OTUyOTI1OSM3MTQ3NTQ0IzIxNTY4Mjk=

Image: https://ml.globenewswire.com/media/NWU2OTVkMzMtY2QwZC00NjFmLTkyY2ItYTI3NDlhMTdhMmFlLTExNjg0MDAtMjAyNS0wOS0xNi1lbg==/tiny/Transom-Capital-Group.png

Source: Transom Capital Group

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
NuCana Reports 'Encouraging' Data From Study to Treat Patients With Lung Cancer
NuCana Reports 'Encouraging' Data From Study to Treat Patients With Lung Cancer
Nov 11, 2024
07:48 AM EST, 11/11/2024 (MT Newswires) -- NuCana ( NCNA ) said Monday that initial data from an ongoing Phase 1b/2 study of NUC-3373 in combination with pembrolizumab indicated a significant reduction in tumor volume in patients with lung cancer. NUC-3373 may be an attractive alternative to pemetrexed in patients with NSCLC and mesothelioma, David Harrison, NuCana's ( NCNA )...
Top Premarket Decliners
Top Premarket Decliners
Nov 11, 2024
07:49 AM EST, 11/11/2024 (MT Newswires) -- Dogwood Therapeutics ( DWTX ) shares slumped nearly 30% pre-bell Monday following a 2.3% loss in the previous session. Sapiens (SPNS) shares retreated 21% after the company reported Q3 revenue that trailed analysts' estimates. Monday.com ( MNDY ) shares fell 14% following a 1.8% gain in the previous session. Vision Marine Technologies (...
Ryvyl Signs MOU for Repayment of Convertible Note, Redemption of  Preferred Stock
Ryvyl Signs MOU for Repayment of Convertible Note, Redemption of Preferred Stock
Nov 11, 2024
07:51 AM EST, 11/11/2024 (MT Newswires) -- Ryvyl ( RVYL ) said Monday it has signed a non-binding memorandum of understanding for the full repayment and termination of an 8% senior convertible note worth $19.0 million and the redemption of all $53.5 million worth of shares of the company's series B convertible preferred stock. Under the terms of the agreement,...
Unicycive Therapeutics Says FDA Accepts New Drug Application for Oxylanthanum Carbonate
Unicycive Therapeutics Says FDA Accepts New Drug Application for Oxylanthanum Carbonate
Nov 11, 2024
07:47 AM EST, 11/11/2024 (MT Newswires) -- Unicycive Therapeutics ( UNCY ) said Monday that the US Food and Drug Administration has accepted its new drug application for oxylanthanum carbonate, and has set a target action date set of June 28, 2025. The drug is a potential treatment for hyperphosphatemia in patients with chronic kidney disease on dialysis, the company...
Copyright 2023-2026 - www.financetom.com All Rights Reserved